Eczema drug from Nektar Therapeutics maintains skin responses in one-year study The results met and in some cases exceeded investor expectations

https://www.statnews.com/2026/02/10/nektar-therapeutics-rezpeg-eczema-drug-maintains-skin-response-study/ By Adam FeuersteinFeb. 10, 2026 Adam Feuerstein, a senior writer and biotech columnist, is the author of Adam’s Biotech Scorecard, a subscriber-only newsletter about the crossroads of drug development, business, Wall Street, and biotechnology.